Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Genentech Licenses Afraxis’ Therapies
by Rick Mullin
February 4, 2013
| A version of this story appeared in
Volume 91, Issue 5
Genentech has signed a licensing deal with Afraxis that gives the Roche subsidiary exclusive worldwide rights to an unspecified portfolio of therapies that Afraxis has under development. Afraxis is best known for its work on Fragile X, a target in autism. Under the deal, Genentech would pay as much as $187 million, including an undisclosed up-front payment and milestone payments. Founded and currently owned by Avalon Ventures, a San Diego venture capital firm, Afraxis is five years old.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X